Viral Kanamalı Ateşler
Özet
Viral kanamalı ateşler, etkenleri çeşitli virüs ailelerine ait zarflı RNA virüslerinin olduğu, terim olarak ateş ve kanama ile seyreden, çoklu organ tutulumu ile seyredebilen zoonotik hastalıklardır. Bu virüslerin doğal rezervuarı insan değildir, genellikle belirli bir coğrafyada yaşayan kemirgenler, primatlar, sinek ve kene gibi rezervuar ve konakları mevcuttur, bu coğrafi alanlarla sınırlı ve sporadik olsalarda bulaştırıcılıklarının yüksek olması nedeni ile bölgesel düzensiz epidemilerde yapabilirler. Ülkemiz için KKKA dışındaki diğer kanamalı ateş hastalıkları seyahat hastalığı şeklinde görünmektedir.
Özellikle hastalık başlangıçta ateş, halsizlik, kas ağrıları, baş ağrısı, karın ağrısı, kusma, gibi özgül olmayan semptomlar gösterdiğinden endemik bölgede yaşama ve/veya seyahat öyküsü gibi epidemiyolojik ilişkinin akla getirilmesi viral kanamalı ateş tanısı için önemlidir.
Referanslar
F. Basler C, Molecular Pathogenesis of Viral Hemorrhagic Fever Semin Immunopathol. 2017 July; 39(5): 551–561.
Paessler S, Walker DH (2013) Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol 8:411–440.
Iannetta M, Di Caro A, Nicastri E, et al.Viral Hemorrhagic Fevers Other than Ebola and Lassa. Infect Dis Clin North Am. 2019 Dec;33(4):977-1002.
Viral Hemorrhagic Fevers (VHFs) j CDC. (5/11/2023 tarihinde https://www.cdc.gov/vhf/virus-families/index.html.adresinden ulaşılmıştır).
Kara A. Kırım Kongo hemorajik ateşi. Çocuk Sağlığı ve Hastalıkları Dergisi 2006; 49: 175-184
6. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. Kırım Kongo Kanamalı Ateşi. (21/12/2024 tarihinde https://hsgm.saglik.gov.tr/depo/birimler/zoonotik-ve-vektorel hastaliklardb/Dokumanlar/Sunumlar/KKKA_Sunum_Hekimlere_Yonelik_2023.pdf. adresinden ulaşılmıştır.)
Mertens M, Schmidt K, Ozkul A,et al. The impact of Crimean-Congo hemorrhagic fever virus on public health. Antiviral Res 2013; 98:248.
Al-Abri SS, Abaidani IA, Fazlalipour M, et al. Current status of Crimean-Congo haemorrhagic fever in the World Health Organization Eastern Mediterranean Region: issues, challenges, and future directions. Int J Infect Dis 2017; 58:82.
Leblebicioglu H, Ozaras R, Sunbul M. Crimean-Congo hemorrhagic fever: A neglected infectious disease with potential nosocomial infection threat. Am J Infect Control 2017.
Pshenichnaya NY, Nenadskaya SA. Probable Crimean-Congo hemorrhagic fever virus transmission occurred after aerosol-generating medical procedures in Russia: nosocomial cluster. Int J Infect Dis 2015; 33:120.
Celikbas AK, Dokuzoğuz B, Baykam Net al. Crimean-Congo hemorrhagic fever among health care workers, Turkey. Emerg Infect Dis. 2014 Mar;20(3):477-9.
Ergonul O, Celikbas A, Yildirim U, et al. Pregnancy and Crimean-Congo haemorrhagic fever. Clin Microbiol Infect 2010; 16:647.
Pshenichnaya NY, Sydenko IS, Klinovaya EP, et al. Possible sexual transmission of Crimean-Congo hemorrhagic fever. Int J Infect Dis 2016; 45:109.
Leblebicioglu H. Crimean-Congo hemorrhagic fever. Up to date. (21/11/2023 tarihinde https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever. adresinden ulaşılmıştır).
Aker S, Akıncı H, Kılıçoğlu C et al. The geographic distribution of cases of Crimean-Congo hemorrhagic fever: Kastamonu, Turkey. Ticks Tick Borne Dis 2015; 6:730.
Spengler JR, Bente DA, Bray Met al. Second International Conference on Crimean-Congo Hemorrhagic Fever. AntiviralRes 2018;150:137–47.
P. Fillâtre, M. Revest, P. Tattevin.Crimean-Congo hemorrhagic fever: An update. Médecine et Maladies Infectieuses 2019; 49: 8 574-585
Yilmaz GR, Buzgan T, Irmak H, et al. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002-2007. Int J Infect Dis. 2009;13(3):380-386.
Drosten C, Gottig S, Schilling S, et al. Rapid detection and quantifi cation of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol 2002; 40: 2323-2330.
Johnson S, Henschke N, Maayan Net al. Ribavirin for treating Crimean Congo haemorrhagic fever. Cochrane. Database Syst Rev.2018; 6:CD012713.
Ergönül Ö, Keske Ş, Çeldir MG, et al. Systematic review and meta-analysis of postexposure prophylaxis for Crimean-Congo hemorrhagic fever virus among healthcare workers. Emerg Infect Dis 2018;24(9):1642–8.
Avšič-Županc T, Saksida A, Korva M. Hantavirus infections. Clin Microbiol Infect. 2019;21:6-16
American Academy of Pediatrics. Hemorrhagic Fevers Caused by Bunyaviruses. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021 Report of the Committee on Infectious Diseases. Itasca, IL:American Academy of Pediatrics: 2021(365-368)
Khaiboullina SF, Morzunov SP, St Jeor SC. Hantaviruses: molecular biology, evolution and pathogenesis. Curr Mol Med 2005;5:773e90.
Vapalahti O, Mustonen J, Lundkvist A, et al. Hantavirus infections in Europe. Lancet Infect Dis 2003; 3:653.
Tulumovic D, Imamovic G, Mesic E, et al. Comparison of the effects of Puumala and Dobrava viruses on early and long-term renal outcomes in patients with haemorrhagic fever with renal syndrome. Nephrology (Carlton). 2010;15(3):340-343.
Vaheri A, Henttonen H, Voutilainen L, et al.Hantavirus infections in Europe and their impact on public health. Rev Med Virol 2013;23:35e49
Vial PA, Valdivieso F, Ferres M, et al. High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial. Clin Infect Dis 2013; 57:943.
Mustanen J. Kidney involvement in hantavirus infections. Up to date.(25/11/2023 tarihinde https://www.uptodate.com/contents/kidney-involvement-in-hantavirus-infections adresinden ulaşılmıştır)
Vial PA, Valdivieso F, Calvo M, et al. A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus. Antivir Ther 2015; 20:377.
Jung J, Ko SJ, Oh HS, et al. Protective Effectiveness of Inactivated Hantavirus Vaccine Against Hemorrhagic Fever With Renal Syndrome. J Infect Dis 2018; 217:1417.
Roy SK, Bhattacharjee S. Dengue virus: epidemiology, biology, and disease aetiology. Can J Microbiol. 2021;67(10):687-702.
Thomas SJ, Rothman AL, Srikiatkhachorn A,et al. Dengue virus infection: Clinical manifestations and diagnosis.Uptodate(25/11/2023 tarihinde https://www.uptodate.com/contents/ Dengue virus infection: Clinical manifestations and diagnosis.adresinden ulaşılmıştır)
Dengue CDC. (23/11/2023 tarihinde https://www.cdc.gov/dengue/healthcare-providers/clinical-presentation.html.adresinden ulaşılmıştır)
Carod-Artal FJ, Wichmann O, Farrar J, et al. Neurological complications of dengue virus infection. Lancet Neurol 2013; 12:906.
Verma R, Sahu R, Holla V. Neurological manifestations of dengue infection: a review. J Neurol Sci 2014; 346:26.
.Miranda CH, Borges Mde C, Matsuno AK, et al. Evaluation of cardiac involvement during dengue viral infection. Clin Infect Dis 2013; 57:812.
Lee IK, Liu JW, Yang KD. Clinical characteristics, risk factors, and outcomes in adults experiencing dengue hemorrhagic fever complicated with acute renal failure. Am J Trop Med Hyg 2009; 80:651.
Laoprasopwattana K, Pruekprasert P, Dissaneewate P, et al. Outcome of dengue hemorrhagic fever-caused acute kidney injury in Thai children. J Pediatr. 2010 Aug;157(2):303-9.
Chan DP, Teoh SC, Tan CS, et al. Ophthalmic complications of dengue. Emerg Infect Dis 2006; 12:285.
Tan LH, Lum LC, Omar SF, et al. Hemophagocytosis in dengue: comprehensive report of six cases. J Clin Virol 2012; 55:79.
Guzman MG, Jaenisch T, Gaczkowski R, et al. Multi-country evaluation of the sensitivity and specificity of two commercially-available NS1 ELISA assays for dengue diagnosis. PLoS Negl Trop Dis 2010; 4.
Beesetti H, Khanna N, Swaminathan S. Investigational drugs in early development for treating dengue infection. Expert Opin Investig Drugs. 2016;25:1059–69.
Tayal A, Kabra SK, Lodha R. Management of Dengue: An Updated Review. Indian J Pediatr. 2023 Feb;90(2):168-177.
Paz-Bailey G, Adams L, Wong JM, et al. Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021. MMWR Recomm Rep 2021; 70:1
Wilder-Smith A. Yellow Fever: Epidemiology,Clinical manifestations and diagnosis. Up to date : Nov 2023. | This topic last updated: Feb 1, 2022.
Monath TP. Yellow fever: An update. Lancet Infect Dis 2001;1:11–20.
Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis 2007; 44:850.
Lopes RL, Pinto JR, Silva Junior GBD, et al. Kidney involvement in yellow fever: a review. Rev Inst Med Trop Sao Paulo 2019; 61:e35.
Mendes ÉA, Pilger DRB, Santos Nastri ACS, et al. Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure. Ann Hepatol 2019; 18:816.
World Health Organization. Vaccines and vaccination against yellow fever. WHO position paper - June 2013 (25/11/2023 tarihinde https://www.who.int/wer/2013/wer8827.pdf?ua=1 adresinden ulaşılmıştır)
World Health Organization. Yellow fever vaccine: WHO position on the use of fractional doses WHO position paper June 2017(25/11/2023tarihinde https://www.who.int/publications/i/item/who-wer9225 adresinden ulaşılmıştır)
Staples JE, Bocchini JA Jr, Rubin L, et al. Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:647.
Khalafallah MT, Aboshady OA, Moawed SA, et al. Ebola virus disease: Essential clinical knowledge. Avicenna J Med 2017;7:96-102.
Feldmann H, Sprecher A, Geisbert TW. Ebola. N Engl J Med 2020; 382:1832.
Chughtai AA, Barnes M, Macintyre CR. Persistence of Ebola virus in various body fluids during convalescence: evidence and implications for disease transmission and control. Epidemiol Infect 2016; 144: 1652–1660.
Nicastri E, Kobinger G, Vairo F, et al. Ebola Virus Disease: Epidemiology, Clinical Features, Management, and Prevention. Infect Dis Clin North Am. 2019;33(4):953-976.
de La Vega MA, Caleo G, Audet J, et al. Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. J Clin Invest 2015;125:4421–8.
Chertow D.S, Bray M, Palmore T. N. Clinical manifestations and diagnosis of Ebola virus disease. Up to date (20/11/2023 tarihinde https://www.uptodate.com/contents/Clinical manifestations and diagnosis of Ebola virus disease adresinden ulaşılmıştır).
Halk Sağlığı Genel Müdürlüğü Ebola Virüs Hastalığı bilgilendirme ve vaka yönetim rehberi 2019.(20/11/2023 tarihinde https://hsgm.saglik.gov.tr/depo/Yayinlarimiz/Rehberler/EVH Vaka Yonetim Rehberi 24 Temmuz 2019.pdf adresinden ulaşılmıştır.
Happi AN, Happi CT, Schoepp RJ. Lassa fever diagnostics: past, present, and future. Curr Opin Virol. 2019;37:132-138.
Schieffelin SJ. Lassa fever. Uptodate: (20/11/2023 tarihinde https://www.uptodate.com/contents/Lassa fever adresinden ulaşılmıştır)
McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986; 314:20.
Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med 2015; 372:1231.
Chahar HS, Bharaj P, Dar L, et al. Co-infections with chikungunya virus and dengue virus in Delhi, India. Emerg Infect Dis 2009; 15(7): 1077-80.
Wilson M E, Lenschow D J. Chikungunya fever: Epidemiology, clinical manifestations, and diagnosis. Up to date : (20/11/2023 tarihinde https://www.uptodate.com/contents/ Chikungunya fever: Epidemiology, clinical manifestations, and diagnosis adresinden ulaşılmıştır)
Rodríguez-Morales AJ, Cardona-Ospina JA, Fernanda Urbano-Garzón S, et al. Prevalence of Post-Chikungunya Infection Chronic Inflammatory Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken) 2016; 68:1849.
Caglioti C, Lalle E, Castilletti C, et al. Chikungunya virus infection: an overview. New Microbiol. 2013; 36(3):211-227.
Chikungunya CDC Yellow Book 2024Travel-Associated Infections & Diseases.(25/11/2023 tarihinde https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/chikungunya adresinden ulaşılmıştır)
